drugset / Trial / NCT03659448
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
RandomizedParallel-groupOpen-labelOther
Summary
The performance of SGM-101, an intraoperative imaging agent, will be compared to that of standard "white light" visualization during surgical resections of colorectal cancer.
Timeline
- Start
- 2019-06-17
- Primary completion
- 2024-11
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SGM-101 | Monoclonal antibody | — | — |